ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on Twitter

Kidney Week

Abstract: SA-PO892

Semaglutide as an Aid to Weight Reduction in Adults With Obesity and Advanced CKD

Session Information

Category: CKD (Non-Dialysis)

  • 2202 CKD (Non-Dialysis): Clinical‚ Outcomes‚ and Trials


  • Bukhari, Sarah, Beaumont Hospital, Dublin, Ireland
  • Cooney, Sarah, Beaumont Hospital, Dublin, Ireland
  • Holland, John, Beaumont Hospital, Dublin, Ireland
  • Alzayer, Husam, Cork University Hospital, Cork, Cork, Ireland
  • Clarkson, Michael, Cork University Hospital, Cork, Cork, Ireland
  • Conlon, Peter J., Beaumont Hospital, Dublin, Ireland

Obesity is becoming more challenging in patients with chronic kidney disease. The efficacy and safety of the GLP-1 analogue semaglutide for weight loss in patients with and without diabetes has been demonstrated. However, there had been limited studies on the use of semaglutide in patients with advanced CKD.


In this retospective study using electronic healthcare records, we evaluated the efficacy and safety of semaglutide for weight reduction in addition to lifestyle intervention in patients with eGFR of <30 ml/min/1.73 m2 and a body mass index of >32 kg/m2. Paired t-test was performed and a p-value of<0.05 was considered statistically significant.


Among the 14 patients included in this study, the mean percentage change in weight loss after three, six and nine months were 5.5%, 8.5% and 9.7%, respectively. After nine months, 7 patients (50%) achieved ≥5% weight loss. The most common reported adverse events were gastrointestinal, including nausea, vomiting and diarrhoea. Two patients discontinued semaglutide because of intolerable gastrointestinal effects. No serious adverse events were noted.


In this set of patients with obesity and advanced CKD, semaglutisde was safe, effective and led to significant reduction in weight.

Comparison of weight at baseline and post-treatment at three, six and nine months
Time point (months)Sample size (N)Mean weight loss Mean percentage change in body weight (%)p-value95% confidence interval
3136.1 kg5.5%< 0.0013.68–8.61
6109.3 kg8.2%< 0.0015.04–13.58
9710.4 kg9.7%< 0.0017.34–13.50